$18.97
At close: Apr 15 EDT
$18.97
0.000.00%
Pre-Market: 5:33 PM EDT
Comments
Loading...
Apellis Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:APLS | Benzinga
Apellis Pharmaceuticals Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for Apellis Pharmaceuticals Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Scotiabank
JP Morgan
RBC Capital
Goldman Sachs
Wedbush
1calculated from analyst ratings
Analyst Ratings for Apellis Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/02/2025 | Buy Now | — | Scotiabank | Greg Harrison40% | $30 → $31 | Maintains | Sector Perform | Get Alert |
| 03/04/2025 | Buy Now | — | JP Morgan | Anupam Rama56% | $50 → $54 | Maintains | Overweight | Get Alert |
| 03/03/2025 | Buy Now | — | RBC Capital | Luca Issi36% | $26 → $25 | Maintains | Sector Perform | Get Alert |
| 03/03/2025 | Buy Now | — | Goldman Sachs | Salveen Richter52% | $36 → $32 | Maintains | Neutral | Get Alert |
| 03/03/2025 | Buy Now | — | Wedbush | Laura Chico43% | $30 → $29 | Maintains | Neutral | Get Alert |
| 03/03/2025 | Buy Now | — | HC Wainwright & Co. | Douglas Tsao49% | $57 → $57 | Reiterates | Buy → Buy | Get Alert |
| 02/13/2025 | Buy Now | — | HC Wainwright & Co. | Douglas Tsao49% | $57 → $57 | Reiterates | Buy → Buy | Get Alert |
| 01/29/2025 | Buy Now | — | RBC Capital | Luca Issi36% | $26 → $26 | Maintains | Sector Perform | Get Alert |
| 01/21/2025 | Buy Now | — | RBC Capital | Luca Issi36% | $26 → $26 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 01/14/2025 | Buy Now | — | HC Wainwright & Co. | Douglas Tsao49% | $57 → $57 | Reiterates | Buy → Buy | Get Alert |
| 12/17/2024 | Buy Now | — | Goldman Sachs | Salveen Richter52% | → $36 | Downgrade | Buy → Neutral | Get Alert |
| 11/21/2024 | Buy Now | — | Morgan Stanley | Judah Frommer66% | → $31 | Initiates | → Equal-Weight | Get Alert |
| 11/07/2024 | Buy Now | — | Baird | Colleen Kusy33% | $92 → $55 | Maintains | Outperform | Get Alert |
| 11/06/2024 | Buy Now | — | Citigroup | Yigal Nochomovitz54% | $63 → $51 | Maintains | Buy | Get Alert |
| 11/06/2024 | Buy Now | — | Goldman Sachs | Salveen Richter52% | $71 → $36 | Maintains | Buy | Get Alert |
| 11/06/2024 | Buy Now | — | RBC Capital | Luca Issi36% | $25 → $24 | Maintains | Sector Perform | Get Alert |
| 11/06/2024 | Buy Now | — | Scotiabank | Greg Harrison40% | $35 → $30 | Maintains | Sector Perform | Get Alert |
| 11/06/2024 | Buy Now | — | Wells Fargo | Derek Archila57% | $43 → $30 | Maintains | Equal-Weight | Get Alert |
| 11/06/2024 | Buy Now | — | Oppenheimer | Justin Kim37% | $65 → $40 | Maintains | Outperform | Get Alert |
| 11/06/2024 | Buy Now | — | Piper Sandler | Biren Amin39% | $40 → $32 | Maintains | Neutral | Get Alert |
| 11/06/2024 | Buy Now | — | HC Wainwright & Co. | Douglas Tsao49% | $83 → $57 | Maintains | Buy | Get Alert |
| 11/06/2024 | Buy Now | — | B of A Securities | Tazeen Ahmad55% | $61 → $47 | Maintains | Buy | Get Alert |
| 11/06/2024 | Buy Now | — | Needham | Joseph Stringer48% | $85 → $60 | Maintains | Buy | Get Alert |
| 11/04/2024 | Buy Now | — | RBC Capital | Luca Issi36% | $25 → $25 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 10/24/2024 | Buy Now | — | Mizuho | Graig Suvannavejh49% | $39 → $38 | Maintains | Neutral | Get Alert |
| 10/16/2024 | Buy Now | — | Scotiabank | Greg Harrison40% | → $35 | Initiates | → Sector Perform | Get Alert |
| 10/16/2024 | Buy Now | — | William Blair | Lachlan Brown23% | — | Initiates | → Outperform | Get Alert |
| 09/24/2024 | Buy Now | — | Wells Fargo | Derek Archila57% | $47 → $43 | Maintains | Equal-Weight | Get Alert |
| 09/23/2024 | Buy Now | — | Baird | Colleen Kusy33% | $96 → $92 | Maintains | Outperform | Get Alert |
| 09/20/2024 | Buy Now | — | Mizuho | Graig Suvannavejh49% | $42 → $39 | Maintains | Neutral | Get Alert |
| 09/20/2024 | Buy Now | — | Needham | Joseph Stringer48% | $85 → $85 | Reiterates | Buy → Buy | Get Alert |
| 09/13/2024 | Buy Now | — | JP Morgan | Anupam Rama56% | $64 → $57 | Maintains | Overweight | Get Alert |
| 08/13/2024 | Buy Now | — | JP Morgan | Anupam Rama56% | $72 → $64 | Maintains | Overweight | Get Alert |
| 08/09/2024 | Buy Now | — | UBS | Eliana Merle42% | $85 → $83 | Maintains | Buy | Get Alert |
| 08/09/2024 | Buy Now | — | Wedbush | Laura Chico43% | $38 → $41 | Maintains | Neutral | Get Alert |
| 08/09/2024 | Buy Now | — | Goldman Sachs | Salveen Richter52% | $66 → $74 | Maintains | Buy | Get Alert |
| 08/09/2024 | Buy Now | — | Baird | Colleen Kusy33% | $86 → $96 | Maintains | Outperform | Get Alert |
| 08/09/2024 | Buy Now | — | Needham | Joseph Stringer48% | $85 → $85 | Reiterates | Buy → Buy | Get Alert |
| 08/02/2024 | Buy Now | — | HC Wainwright & Co. | Douglas Tsao49% | $92 → $83 | Maintains | Buy | Get Alert |
| 08/02/2024 | Buy Now | — | Goldman Sachs | Salveen Richter52% | $77 → $66 | Maintains | Buy | Get Alert |
| 08/02/2024 | Buy Now | — | Needham | Joseph Stringer48% | $85 → $85 | Reiterates | Buy → Buy | Get Alert |
| 07/31/2024 | Buy Now | — | Jefferies | Akash Tewari43% | $80 → $80 | Maintains | Buy | Get Alert |
| 07/26/2024 | Buy Now | — | Baird | Colleen Kusy33% | $100 → $86 | Maintains | Outperform | Get Alert |
| 07/23/2024 | Buy Now | — | Baird | Colleen Kusy33% | $100 → $100 | Maintains | Outperform | Get Alert |
| 07/17/2024 | Buy Now | — | Goldman Sachs | Salveen Richter52% | $90 → $77 | Maintains | Buy | Get Alert |
| 06/28/2024 | Buy Now | — | Baird | Colleen Kusy33% | $100 → $100 | Maintains | Outperform | Get Alert |
| 05/31/2024 | Buy Now | — | Piper Sandler | Biren Amin39% | → $46 | Initiates | → Neutral | Get Alert |
| 05/28/2024 | Buy Now | — | HC Wainwright & Co. | Douglas Tsao49% | $92 → $92 | Reiterates | Buy → Buy | Get Alert |
| 05/23/2024 | Buy Now | — | Wells Fargo | Derek Archila57% | $57 → $48 | Maintains | Equal-Weight | Get Alert |
| 05/08/2024 | Buy Now | — | Needham | Joseph Stringer48% | $85 → $85 | Reiterates | Buy → Buy | Get Alert |
| 05/08/2024 | Buy Now | — | Citigroup | Yigal Nochomovitz54% | $67 → $60 | Maintains | Buy | Get Alert |
| 05/08/2024 | Buy Now | — | HC Wainwright & Co. | Douglas Tsao49% | → $92 | Reiterates | Buy → Buy | Get Alert |
| 05/08/2024 | Buy Now | — | UBS | Eliana Merle42% | $89 → $85 | Maintains | Buy | Get Alert |
| 04/29/2024 | Buy Now | — | Mizuho | Graig Suvannavejh49% | $60 → $52 | Maintains | Neutral | Get Alert |
| 04/26/2024 | Buy Now | — | HC Wainwright & Co. | Douglas Tsao49% | $92 → $92 | Reiterates | Buy → Buy | Get Alert |
| 04/25/2024 | Buy Now | — | Needham | Joseph Stringer48% | $85 → $85 | Reiterates | Buy → Buy | Get Alert |
| 04/17/2024 | Buy Now | — | Wedbush | Laura Chico43% | $67 → $57 | Maintains | Neutral | Get Alert |
| 04/15/2024 | Buy Now | — | HC Wainwright & Co. | Douglas Tsao49% | $92 → $92 | Reiterates | Buy → Buy | Get Alert |
| 04/09/2024 | Buy Now | — | Needham | Joseph Stringer48% | $85 → $85 | Reiterates | Buy → Buy | Get Alert |
| 03/27/2024 | Buy Now | — | Mizuho | Graig Suvannavejh49% | $60 → $60 | Maintains | Neutral | Get Alert |
| 03/06/2024 | Buy Now | — | JP Morgan | Anupam Rama56% | $78 → $79 | Maintains | Overweight | Get Alert |
| 03/04/2024 | Buy Now | — | UBS | Eliana Merle42% | $87 → $89 | Maintains | Buy | Get Alert |
| 02/28/2024 | Buy Now | — | HC Wainwright & Co. | Douglas Tsao49% | $92 → $92 | Reiterates | Buy → Buy | Get Alert |
| 02/28/2024 | Buy Now | — | Wedbush | Laura Chico43% | $60 → $67 | Maintains | Neutral | Get Alert |
| 02/16/2024 | Buy Now | — | Mizuho | Graig Suvannavejh49% | $49 → $60 | Maintains | Neutral | Get Alert |
| 02/06/2024 | Buy Now | — | Baird | Colleen Kusy33% | → $81 | Reiterates | Outperform → Outperform | Get Alert |
| 02/05/2024 | Buy Now | — | Jefferies | Akash Tewari43% | $68 → $80 | Upgrade | Hold → Buy | Get Alert |
| 01/30/2024 | Buy Now | — | Oppenheimer | Justin Kim37% | $75 → $79 | Maintains | Outperform | Get Alert |
| 01/24/2024 | Buy Now | — | Needham | Joseph Stringer48% | $70 → $75 | Maintains | Buy | Get Alert |
| 01/17/2024 | Buy Now | — | Baird | Colleen Kusy33% | $71 → $81 | Maintains | Outperform | Get Alert |
| 01/17/2024 | Buy Now | — | HC Wainwright & Co. | Douglas Tsao49% | $82 → $92 | Maintains | Buy | Get Alert |
| 01/12/2024 | Buy Now | — | Wedbush | Laura Chico43% | $39 → $60 | Maintains | Neutral | Get Alert |
| 01/11/2024 | Buy Now | — | Raymond James | Steven Seedhouse59% | $67 → $106 | Maintains | Strong Buy | Get Alert |
| 01/09/2024 | Buy Now | — | Goldman Sachs | Salveen Richter52% | $65 → $90 | Maintains | Buy | Get Alert |
| 12/15/2023 | Buy Now | — | Citigroup | Yigal Nochomovitz54% | $70 → $67 | Maintains | Buy | Get Alert |
| 12/15/2023 | Buy Now | — | Oppenheimer | Justin Kim37% | $88 → $75 | Maintains | Outperform | Get Alert |
| 12/15/2023 | Buy Now | — | Raymond James | Steven Seedhouse59% | $93 → $67 | Maintains | Strong Buy | Get Alert |
| 12/14/2023 | Buy Now | — | Needham | Joseph Stringer48% | $63 → $56 | Maintains | Buy | Get Alert |
| 12/14/2023 | Buy Now | — | Wells Fargo | Derek Archila57% | $67 → $54 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 12/05/2023 | Buy Now | — | B of A Securities | Tazeen Ahmad55% | $52 → $85 | Upgrade | Neutral → Buy | Get Alert |
| 11/09/2023 | Buy Now | — | Goldman Sachs | Salveen Richter52% | → $74 | Initiates | → Buy | Get Alert |
| 11/02/2023 | Buy Now | — | Mizuho | Graig Suvannavejh49% | → $42 | Initiates | → Neutral | Get Alert |
| 11/02/2023 | Buy Now | — | Raymond James | Steven Seedhouse59% | $92 → $93 | Maintains | Strong Buy | Get Alert |
| 11/01/2023 | Buy Now | — | Needham | Joseph Stringer48% | $60 → $63 | Maintains | Buy | Get Alert |
| 10/12/2023 | Buy Now | — | B of A Securities | Tazeen Ahmad55% | $44 → $46 | Maintains | Neutral | Get Alert |
| 10/06/2023 | Buy Now | — | Citigroup | Yigal Nochomovitz54% | $54 → $70 | Maintains | Buy | Get Alert |
| 10/06/2023 | Buy Now | — | JP Morgan | Anupam Rama56% | $60 → $81 | Upgrade | Neutral → Overweight | Get Alert |
| 10/06/2023 | Buy Now | — | Raymond James | Steven Seedhouse59% | $89 → $92 | Maintains | Strong Buy | Get Alert |
| 09/26/2023 | Buy Now | — | HC Wainwright & Co. | Douglas Tsao49% | → $82 | Reiterates | Buy → Buy | Get Alert |
| 09/20/2023 | Buy Now | — | HC Wainwright & Co. | Douglas Tsao49% | → $82 | Reiterates | Buy → Buy | Get Alert |
| 09/15/2023 | Buy Now | — | Wells Fargo | Derek Archila57% | $34 → $64 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 09/14/2023 | Buy Now | — | HC Wainwright & Co. | Douglas Tsao49% | → $82 | Reiterates | Buy → Buy | Get Alert |
| 09/08/2023 | Buy Now | — | B of A Securities | Tazeen Ahmad55% | $40 → $43 | Maintains | Neutral | Get Alert |
| 08/30/2023 | Buy Now | — | Citigroup | Yigal Nochomovitz54% | $45 → $54 | Maintains | Buy | Get Alert |
| 08/30/2023 | Buy Now | — | Needham | Joseph Stringer48% | → $60 | Reiterates | Buy → Buy | Get Alert |
| 08/29/2023 | Buy Now | — | Stifel | Annabel Samimy66% | $60 → $65 | Maintains | Buy | Get Alert |
| 08/24/2023 | Buy Now | — | Needham | Joseph Stringer48% | → $60 | Reiterates | Buy → Buy | Get Alert |
| 08/23/2023 | Buy Now | — | Oppenheimer | Justin Kim37% | — | Reiterates | Outperform → Outperform | Get Alert |
| 08/23/2023 | Buy Now | — | Wedbush | Laura Chico43% | → $29 | Reiterates | Neutral → Neutral | Get Alert |
| 08/23/2023 | Buy Now | — | UBS | Eliana Merle42% | $60 → $64 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Apellis Pharmaceuticals (APLS) stock?
The latest price target for Apellis Pharmaceuticals (NASDAQ:APLS) was reported by Scotiabank on April 2, 2025. The analyst firm set a price target for $31.00 expecting APLS to rise to within 12 months (a possible 63.42% upside). 57 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Apellis Pharmaceuticals (APLS)?
The latest analyst rating for Apellis Pharmaceuticals (NASDAQ:APLS) was provided by Scotiabank, and Apellis Pharmaceuticals maintained their sector perform rating.
When was the last upgrade for Apellis Pharmaceuticals (APLS)?
The last upgrade for Apellis Pharmaceuticals Inc happened on February 5, 2024 when Jefferies raised their price target to $80. Jefferies previously had a hold for Apellis Pharmaceuticals Inc.
When was the last downgrade for Apellis Pharmaceuticals (APLS)?
The last downgrade for Apellis Pharmaceuticals Inc happened on December 17, 2024 when Goldman Sachs changed their price target from N/A to $36 for Apellis Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for Apellis Pharmaceuticals (APLS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Apellis Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Apellis Pharmaceuticals was filed on April 2, 2025 so you should expect the next rating to be made available sometime around April 2, 2026.
Is the Analyst Rating Apellis Pharmaceuticals (APLS) correct?
While ratings are subjective and will change, the latest Apellis Pharmaceuticals (APLS) rating was a maintained with a price target of $30.00 to $31.00. The current price Apellis Pharmaceuticals (APLS) is trading at is $18.97, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.